Where does Ultragenyx Pharmaceutical's cash flow data come from?

Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$185M-43.9%	-$128.56M+28.7%	-$180.41M-56.9%	-$114.95M+23.9%	-$151M-13.4%
Depreciation and amortization	$8M-8.9%	$8.79M+2.1%	$8.61M0.0%	$8.61M-4.3%	$9M-5.6%
Change in accounts receivable	-$19M-156%	$33.83M+724%	-$5.43M-143%	$12.59M+226%	-$10M-148%
Change in inventories	$4M—	——	$5.6M—	——	$1M-55.5%
Other working capital changes	-$1M—	——	$273K-80.8%	$1.42M+42.0%	$1M—
Change in deferred revenue	——	——	——	——	——
Net cash from operating activities	-$197M-97.3%	-$99.83M-9.2%	-$91.42M+15.9%	-$108.75M+34.5%	-$166M-109%
Capital expenditures	$1M+6.6%	$938K-26.6%	$1.28M-54.1%	$2.78M+178%	$1M+513%
Purchases of investments	$131M-14.7%	$153.56M+806%	$16.94M+9.3%	$15.5M—	$0-100%
Proceeds from maturities/sales of investments	$88M+61,638%	-$143K—	——	——	$137M—
Purchases of intangible assets	$5M—	——	——	——	$15M+2,900%
Other investing activities	$0—	——	$185K+110%	$88K-91.2%	$1M—
Net cash from investing activities	-$49M—	——	$117.18M+64.9%	$71.07M-40.8%	$120M—
Effect of exchange rate changes on cash	-$1M—	——	$294K-91.3%	$3.36M+236%	$1M+151%
Net increase (decrease) in cash	-$247M-212%	$221.46M+750%	$26.06M-47.3%	$49.49M+210%	-$45M—
Accretion (Amortization) of Discounts and Premiums, Investments	$1M+93.8%	$516K-26.7%	$704K-9.7%	$780K-61.0%	$2M-37.1%
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost	$30M-19.5%	$37.29M+0.1%	$37.27M-3.1%	$38.45M-3.9%	$40M-0.3%
Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities	-$57M-254%	$37.01M-18.0%	$45.12M+545%	-$10.14M+78.9%	-$48M-203%
Prepaid expenses and other current assets	$9M+228%	$2.74M—	——	$165K-99.0%	$17M—
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties	$21M+7.9%	$19.47M+37.6%	$14.15M+0.8%	$14.04M+0.3%	$14M-9.6%
Non Cash Royalty Revenue	$20M-46.8%	$37.58M+50.9%	$24.91M-18.3%	$30.51M+60.6%	$19M-43.4%
Other Noncash Income (Expense)	-$1M—	——	$273K-80.8%	$1.42M+42.0%	$1M—
Payment for (Proceeds from) Other Investing Activity	$0—	——	$185K+110%	$88K-91.2%	$1M—
Payments to Acquire Intangible Assets	$5M—	——	——	——	$15M+2,900%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$88M+7.2%	$82.12M-39.4%	$135.59M+51.8%	$89.3M-34.8%	$137M+14.8%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	-$1M—	——	$294K-91.3%	$3.36M+236%	$1M+151%
Free cash flow	-$198M-96.5%	-$100.77M-8.7%	-$92.7M+16.9%	-$111.53M+33.2%	-$167M-110%
Free cash flow	-$198M-96.5%	-$100.77M-8.7%	-$92.7M+16.9%	-$111.53M+33.2%	-$167M-110%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Ultragenyx Pharmaceutical's cash flow data come from?: Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.